Pilot study to look at the feasibility of using remote vital sign monitoring app to improve the care of patients being treated at home with highly myelosuppressive chemotherapy.

Not Applicable

• Conditions: Myelosuppression; Cancer; Cancer - Any cancer

• Registration Number: ACTRN12614000780651
• Lead Sponsor: View Health Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-07-21
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients being treated with highly myelosuppressive chemotherapy (e.g. regimens for high grade lymphoma or leukaemia).

Exclusion Criteria

Patients under 18 years of age.
Patients with pacemakers.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess the feasibility of using an intelligent, mobile, remote, vital sign monitoring device (Securafone (Registered Trademark) Health) to monitor patients receiving highly myelosuppressive chemotherapy regimens at home with Chemo@home. <br>Feasibility is assessed through a simple patient questionnaire. [12 months];To assess the validity of the data by calculating the correlation between the values measured by the continuous device and the conventional measurement.[12 months]

Secondary Outcome Measures

Name	Time	Method
il[Nil]